Abstract
Although still being refined, MUNE has provided important information about disease course in patients with ALS, and has served as a sensitive marker of motor neurone loss in animal models. Modifications in current techniques have the potential to reduce variability of measurement and improve ease of use. As a surrogate outcome measure in phase II clinical trials, MUNE may reduce sample size required to show a meaningful effect of therapy as compared with other commonly used measures.